CD33 and acute myeloid leukemia: Human CD33 on Acute Myeloid Leukaemia blasts has been successfully targeted by Gemtuzumab ozogamicin (GO), an anti-CD33 humanized antibody conjugated to calicheamicin in Phase III clinical trials [27].